What Conditions Do GLP-1s Treat?

“GLP-1 clinical studies focus on both primary and secondary health conditions.”

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications best known for treating type 2 diabetes and obesity, but clinical evidence increasingly points to a much broader range of applications. By mimicking a natural gut hormone, these drugs influence insulin release, appetite regulation, systemic inflammation, and cardiovascular function, which makes them one of the most medically significant drug classes of the past decade.

When these actions are combined, they address the core drivers of metabolic syndrome: excess weight, elevated blood pressure, poor insulin sensitivity, and lipid imbalances. Beyond simple weight loss, these mechanisms harmonize peptide hormones, lower blood pressure, decrease harmful visceral fat, and reduce systemic inflammation. Because GLP-1 medications reduce systemic inflammation, protect blood vessels, and alter core metabolic pathways, their medical applications continue to expand across practice areas.

Which Primary Conditions Are Treated with GLP-1s?

• Type 2 Diabetes: GLP-1 receptor agonists are a first-line treatment option for type 2 diabetes. They lower blood sugar by triggering insulin release, suppressing glucagon, and slowing digestion to prevent post-meal glucose spikes. GLP-1 RAs begin lowering post-meal blood sugar within hours of the first dose. However, measurable reductions in daily blood glucose typically take 1–2 weeks, and meaningful improvements in 3-month HbA1c levels generally require 12–16 weeks as dosage is gradually increased.
• Chronic Weight Management: At higher therapeutic doses, GLP-1 receptor agonists are approved for chronic weight management. They bind to brain regions that govern hunger and satiety, lower appetite, increase fullness after small meals, and slow gastric emptying—substantially reducing daily caloric intake and quieting persistent food cravings. Many patients achieve 10%–15% or more total body weight loss. These medications also improve associated metabolic markers, including blood pressure, cholesterol, and blood sugar levels.

What Are Approved and Emerging Uses of GLP-1?

• Cardiovascular Disease: Certain GLP-1 receptor agonists carry FDA approval to reduce the risk of major adverse cardiac events—including heart attack and stroke—in patients with established cardiovascular disease or high-risk metabolic profiles. Clinical studies show GLP-1 RAs lower cardiovascular risk by reducing systemic inflammation, improving blood pressure and glycemic control, promoting weight loss, and easing the mechanical workload on the heart. They also reduce symptoms and hospitalizations associated with heart failure with preserved ejection fraction (HFpEF) and help heart muscle cells process energy more efficiently under stress.
• Metabolic Dysfunction-Associated Steatohepatitis: GLP-1 receptor agonists such as semaglutide and liraglutide are under active clinical evaluation—and in some cases approved—for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. These drugs reduce liver fat, inflammation, and scarring through both indirect metabolic improvements (weight loss, better glycemic control) and direct cellular anti-inflammatory actions. Clinical trials demonstrate histologic resolution of MASH and measurable improvements in fibrosis scores, establishing GLP-1 RAs as a promising hepatological intervention.
• Obstructive Sleep Apnea: GLP-1 receptor agonists are approved to help treat moderate-to-severe obstructive sleep apnea, particularly in patients where excess weight is a contributing factor. They reduce OSA primarily by promoting significant weight loss, which shrinks fatty tissue deposits around the neck, tongue, and upper airway—preventing airway collapse during sleep and substantially lowering the apnea-hypopnea index (AHI). Additionally, systemic inflammation linked to obesity and tissue hypoxia improves with treatment, reducing swelling in the upper airway passages.
• Chronic Kidney Disease: GLP-1 receptor agonists provide clinically meaningful protective benefits for kidney function, particularly in patients with overlapping metabolic conditions such as type 2 diabetes and obesity. They protect kidney tissue by lowering blood sugar, reducing inflammation, decreasing urinary albumin excretion, and promoting weight loss. Major clinical trials, including the FLOW trial, demonstrate that specific GLP-1 medications significantly slow the progression of chronic kidney disease and lower the risk of kidney failure. They also substantially decrease a key biomarker of reduced kidney stress. So, GLP-1 RAs are a powerful addition to, rather than a replacement for standard therapies.

Which Conditions Are Under Study for GLP-1 Use?

• Addiction and Substance Use: Researchers are studying GLP-1 receptor agonists for their potential to reduce cravings related to alcohol, nicotine, and other substances. Early research suggests these drugs may help with smoking addiction by dampening the brain's reward pathways, reducing nicotine cravings, and preventing post-cessation weight gain. Similarly, anecdotal reports and early clinical data suggest GLP-1 medications may reduce compulsive or impulsive behavior patterns, including shopping addiction, by quieting dopamine-driven reward surges. However, GLP-1 RAs are not yet FDA-approved for any substance use disorder or smoking cessation indication, and results vary widely among individuals.
• Neurodegenerative Disorders: Emerging research—including observations highlighted by the Alzheimer's Association—indicates that GLP-1 receptor agonists may help protect the brain by reducing neuroinflammation, improving cellular energy metabolism, and lowering toxic protein buildup associated with Alzheimer's and Parkinson's disease. Early human trials show promising signals, including slowed brain volume loss and improved cerebral glucose utilization. Large population-based studies show that individuals taking GLP-1 medications for diabetes have a statistically lower risk of developing dementia or Parkinson's disease. Experts emphasize these drugs should not replace standard neurological medications.
• Osteoarthritis: GLP-1 receptor agonists are being evaluated for their ability to lower joint inflammation and ease knee pain in patients with osteoarthritis. Their primary benefit appears to stem from significant weight-driven reduction in mechanical load on weight-bearing joints such as the knees. Beyond weight reduction, emerging clinical and preclinical research indicates these drugs may directly lower systemic and joint-specific inflammation, potentially slowing cartilage breakdown. Clinical studies document reductions in inflammatory biomarkers and key interleukins during treatment. Long-term data also suggest a reduced likelihood of requiring total knee replacement surgery among GLP-1 users.
• ADHD: GLP-1 receptors are present in brain regions that govern reward and impulse control, overlapping significantly with the dopamine pathways implicated in attention-deficit/hyperactivity disorder (ADHD). Animal and early human studies show these drugs can dampen intense reward surges, which may lower general impulsivity or addictive tendencies. Some patients report feeling calmer or less impulsive during treatment. However, clinical evidence confirming direct improvements in attention or executive function is currently lacking. Better metabolic health, improved sleep quality, and reduced brain fog may contribute to a subjective sense of improved focus—even though GLP-1 RAs do not directly target ADHD pathways. This area remains investigational.

Frequently Asked Questions

Do GLP-1s provide relief from hormone imbalance?

Clinical data indicates that both estrogen and glucagon-like peptide-1 act on converging pathways in the brain’s appetite center and directly improves how a woman’s body handles energy by reducing adipose fat-tissue storage. But, for those taking oral estrogen, GLP-1 RA side effects like gastrointestinal discomfort can reduce absorption, so transdermal patches or gels should be used for HRT. On the other hand, with PCOS estrogen dominance, GLP-1 non-hormonal receptor agonists can indirectly help by promoting weight loss that aids in regulating sex hormone production in the body’s fat tissue.

Do prescriptive GLP-1 receptor agonists target fat loss?

No, just like other methods designed to promote significant weight loss, about 25% to 40% of the weight lost can be lean muscle tissue if left totally unmitigated. But, the good news is that GLP-1 RAs will promote fat loss, including harder-to-shed visceral fat stored around abdominal organs. After all, glucagon-like peptide-1 naturally reduces food chatter to enhance feelings of fullness sooner and reduce the overall calorie intake. But, lean mass loss is inevitable as rapid weight loss leads to a smaller body that requires less muscle to function properly. Adding resistance training and following a protein-forward diet helps reverse muscle loss.

Do GLP-1 RAs have a role as a cancer therapeutic?

Due in part to the widespread use of these latest weight loss drugs, GLP-1 RAs  may have an ongoing therapeutic role for intervention of obesity-related cancers. After all, metabolic insulin disturbances, systemic inflammation, and excess fat storage are linked to both tumor progression and recurrence of obesity-related malignancies, particularly in postmenopausal breast and endometrial cancers. So, by reducing circulating insulin and glucose levels, lowering inflammation, and promoting sustainable weight loss, GLP-1 RAs may also have a greater role for chemoprevention.

_______________________

GLP-1 medications are primarily used to treat type 2 diabetes and chronic weight management for obesity or overweight with metabolically-related health conditions. These synthetic incretin mimetics are also used or approved to reduce the risk of cardiovascular events, treat moderate-to-severe obstructive sleep apnea, and manage metabolic-associated steatohepatitis (MASH). , but they are also approved or actively studied for several other conditions. Because GLP-1 medications reduce systemic inflammation, protect blood vessels, and alter metabolic pathways, their medical applications continue to expand. At Metabolic Research Center Lincoln, our goal is to provide the GLP-1 support needed to create a customized program that preserves crucial muscle mass, limits the common side effects of using a GLP-1 receptor agonist, and produces the changes your body needs for sustainable weight control.